Lipocine shares tumble (again) after the FDA shows another testosterone therapy the door
Another testosterone therapy is getting the heave ho at the FDA.
Lipocine $LPCN reported this morning that the agency has issued a complete response …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
